Geode Capital Management LLC Trims Holdings in OptiNose, Inc. (NASDAQ:OPTN)

Geode Capital Management LLC trimmed its holdings in shares of OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,167 shares of the company's stock after selling 1,212,166 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of OptiNose worth $576,000 as of its most recent SEC filing.

Separately, State Street Corp grew its position in OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company's stock worth $229,000 after purchasing an additional 42,500 shares during the last quarter. 85.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on OPTN. HC Wainwright reissued a "neutral" rating and issued a $9.00 price objective (down from $18.00) on shares of OptiNose in a report on Friday, March 21st. Piper Sandler reissued a "neutral" rating and set a $9.00 price target (down from $15.00) on shares of OptiNose in a research report on Friday, March 21st. Finally, Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and dropped their price objective for the company from $17.00 to $9.00 in a report on Thursday, March 20th.

Insider Activity at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total transaction of $33,729.04. Following the sale, the chief executive officer now owns 126,931 shares of the company's stock, valued at $671,464.99. The trade was a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 8,213 shares of company stock valued at $43,643. 2.30% of the stock is owned by insiders.

OptiNose Trading Down 0.1 %

NASDAQ:OPTN traded down $0.01 during trading hours on Thursday, reaching $9.39. 9,035 shares of the company were exchanged, compared to its average volume of 59,739. The stock's 50-day moving average is $8.23 and its 200-day moving average is $7.57. OptiNose, Inc. has a twelve month low of $4.82 and a twelve month high of $20.03. The firm has a market cap of $95.09 million, a PE ratio of -2.24 and a beta of -0.88.

OptiNose (NASDAQ:OPTN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.70) by $0.67. The company had revenue of $21.47 million during the quarter, compared to analysts' expectations of $21.02 million. As a group, research analysts anticipate that OptiNose, Inc. will post -3.22 EPS for the current year.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.